COMP <GO>
PBH vs JNJ // EV/EBITDA & P/E VALUATION
Prestige Consumer Healthcare Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PBH 3
— JNJ 9
▲ EV/EBITDA & P/E VALUATION LEADER: PBH
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
valuation
7.0x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 67.90% | -13.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 25.50% | -11.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.0x | 18.5x | -11.50 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | 2.97% | +7.70 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | 34.70% | -6.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 17.50% | 28.50% | -11.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | 6.00% | -10.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 5.59 | -3.38 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 62.1 | -7.96 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 23.0x | -11.70 | PBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.31B | $662.49B | -$660.18B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | JNJ REV | PBH GROSS % | JNJ GROSS % | PBH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $94.19B | 54.7% | 67.9% | $246.4M | $19.70B |
| FY 2024 | $1.14B | $88.82B | 55.8% | 69.1% | $243.3M | $19.84B |
| FY 2023 | $1.13B | $85.16B | — | — | $248.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
JNJ // BETA 1.08